On Invalid Date, Regulus Therapeutics (NASDAQ: RGLS) reported Q4 2023 earnings per share (EPS) of -$0.39, up 2.5% year over year. Total Regulus Therapeutics earnings for the quarter were -$8.06 million. In the same quarter last year, Regulus Therapeutics's earnings per share (EPS) was -$0.40.
As of Q1 2024, Regulus Therapeutics's earnings has grown year over year. Regulus Therapeutics's earnings in the past year totalled -$30.04 million.
What is RGLS's earnings date?
Regulus Therapeutics's earnings date is Invalid Date. Add RGLS to your watchlist to be reminded of RGLS's next earnings announcement.
What was RGLS's revenue last quarter?
On Invalid Date, Regulus Therapeutics (NASDAQ: RGLS) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Regulus Therapeutics's revenue was $0.00.
What was RGLS's revenue growth in the past year?
As of Q1 2024, Regulus Therapeutics's revenue has grown null year over year. Regulus Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.